29 results about "Triaziquone" patented technology

The invention relates to a composition comprising (i) more than 0.5 wt.% of a compound according to formula (Ia) or a salt, hydrate, stereoisomer, tautomer or N-oxide thereof, based on the total weight of the composition, and (ii) 4,4ʼ,4ʼʼ-(1,3,5-triazin-2,4,6-triyltriimino)tris-benzoic acid tris(2-ethylhexyl)ester (INCI ethylhexyl triazone).

There is provided herein a compound of formula I, wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of inflammation.

The present invention belongs to the field of chemical medicine and provides a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The present invention provides a class of compounds with a skeleton of thiophenopyrrolotriazinone, which can be used to prepare NLRP3 inflammasome inhibitors and provides a new option for preparing drugs for treating diseases caused by abnormal activation of NLRP3 inflammasome.

The invention relates to the technical field of skin care products, in particular to a sunscreen composition as well as a preparation method and application thereof. The sunscreen composition is prepared from a carrier, a sunscreen agent component and a sunscreen synergistic component, wherein the sunscreen agent component and the sunscreen synergistic component are entrapped by the carrier; the sunscreen agent component is prepared from avobenzone, diethylhexyl butyrylamide triazinone and bis-ethylhexyloxyphenol methoxyphenyl triazine; the sunscreen synergistic component is prepared from carrot seed oil and herba siegesbeckiae extract. According to the sunscreen composition, AVB, DHBT and BEMT are combined with sunscreen synergistic components including carrot seed oil and herba siegesbeckiae extract, and the sunscreen composition with remarkably excellent sunscreen capacity and safety is obtained through the synergistic effect of all the components and has important value in the related production field of skin care products.

The present application relates to compounds of formula (I) wherein P, Q, A, B, m, n, R1, R2 and R3 are as defined in formula (I); the compounds are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and are useful in the treatment or prevention of nervous, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which mGlu7 metabotropic receptor subtype is involved. The present application also relates to pharmaceutical compositions comprising such compounds; methods of making such compounds and such compositions; and the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases, in which mGlu7 is involved. # imgabs0 #

The invention discloses a preparation method of 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H)-ketone and a preparation method of the 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H) The preparation method comprises the following steps: dissolving 3, 3-dimethyl-2-oxobutyric acid methyl ester in a solvent, adjusting the pH value to be acidic, then adding thiocarbazide and DMAP (Dimethylamino Phosphate), carrying out a heating reaction, and after the reaction is finished, carrying out filtering, solid separation, washing and vacuum drying in sequence to prepare 4-amino-6-tert-butyl-3-sulfydryl-1, 2, 4-triazine-5 (4H)-ketone. The extraction solvents used in all the steps are the same, the reaction solvent is mainly water and can be removed through anhydrous sodium sulfate, and when the reaction solvent is alcohol, the alcohol can be removed through rotary evaporation. Therefore, the discharge amount of three wastes in the reaction is small, the potential safety hazard is small, and the product yield and purity are high; raw material cost is low, and industrial production is facilitated.

The invention discloses a chiral pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound and a preparation method of the chiral pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound. According to the method, under the action of a copper catalyst generated in situ by a metal copper precursor and a chiral pyridine bisoxazoline ligand in a reaction medium, an ethynyl methylene cyclocarbamate compound and an azomethine compound are subjected to a [3 + 3] cyclization reaction, and the chiral pyrazolo [1, 3-a] [1, 2, 4] triazine-6-ketone compound is obtained with high yield and high enantioselectivity. The method has the characteristics of cheap catalyst precursor, easily available ligand, high activity, high selectivity, mild reaction conditions, simplicity and convenience in operation and the like.

The invention discloses a triazinone compound and medical application thereof.The compound shown in the formula I and pharmaceutically acceptable salt of the compound can serve as an NLRP3 inflammasome inhibitor and can be used for preparing drugs for preventing or treating NLRP3 inflammasome mediated diseases.

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R1 is C1-C3alkyl optionally substituted with F, C3-C6cycloalkyl, C1-C3alkoxy; X represents a bond or C1-C3alkylene optionally substituted with OH, ONO, ONO2; R2 is H, OH, ONO, ONO2, C(O)OH, C(O)OC1-C3alkyl, CHO, CN, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl, CR8═N—OR9, CR8═N—NR10R11, CR8═NR12 or CR8═N—ONO2; R3 is C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, C1-C3alkoxy, C3-C6cycloalkyl; C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl; R4 is C1-C6alkyl optionally substituted with C3-C6cycloalkyl, C1-C6alkoxy, F, ONO, ONO2; C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; R5 is H, SO2N—R13R14, NHSO2NR13R14; R6 is H or C1-C3alkyl; R7 is H, C1-C3alkyl, C1-C3alkoxy, C1-C3alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said heterocyclic ring are independently optionally substituted by C1-C3alkyl, F; R8 is H, CH3 or C2H5; R9: H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R10 and R11 are each independently H, C1-C3alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; i or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrolidine, piperidine, morpholine, piperazine and homopiperazine, wherein said heterocyclic ring is optionally substituted with C1-C3 alkyl; R12 is C1-C3 alkyl optionally substituted with OH, ONO, ONO2, CN, COOH, COOC1-C3alkyl, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl; R13 and R14 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6Cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrolidine, piperidine, morpholine, piperazine, homopiperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with R15; R15 is C1-C6alkyl optionally substituted with halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR16, NR17R18, C═NR19, or with a tetrazole group which is optionally substituted with C1-C3alkyl; or a heteroaryl ring which is optionally substituted with F, wherein the at least one heteroatom of said heteroaryl ring is nitrogen; R16 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR17R18, or with a heteroaryl ring, wherein the at least one heteroatom of said heteroaryl ring is nitrogen, and wherein preferably said heteroaryl ring is selected from pyrrolidine, piperidine, piperazine, morpholine, pyrrole, and imidazole, wherein nitrogen atom is directly bound to C1-C4 alkyl; R17 and R18 are each independently H or C1-C4alkyl optionally substituted with ONO, ONO2; R19 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6Cycloalkyl; and their use in methods of treating or preventing a disease alleviated by inhibition of PDE-5 in a human or in a non-human mammal.

The utility model discloses a triazinone hydrolysis device which comprises a reaction kettle, the upper surface of the reaction kettle is fixedly connected with a motor, the output end of the motor is fixedly connected with a rotating column, the outer surface of the rotating column is fixedly connected with four inclined scrapers, the middle of the outer surface of the reaction kettle is fixedly connected with an oil collecting block, and the oil collecting block is fixedly connected with an oil outlet of the oil collecting block. An oil removing groove is formed in the oil collecting block, the oil removing groove is communicated with the interior of the reaction kettle, in-groove baffles are fixedly connected to the lower surfaces of the four inclined scraping plates, the in-groove baffles are located in the oil removing groove, and four oil removing pipes are fixedly connected to the lower surface of the oil collecting block; oil storage pipes are fixedly connected to the lower surfaces of the four oil removing pipes, oil outlet pipes are fixedly connected to the lower surfaces of the oil storage pipes, and mechanical valves are fixedly connected to the interiors of the oil outlet pipes. The inclined scraping plate rotates along with the rotation of the rotating column, and the oil dirt moves in the specific direction along the track of the scraping plate by utilizing the inclination angle and the rotating force, so that the oil dirt collecting efficiency is improved.

The application provides a 1,2,3-benzotriazine-4(3H)-ketone selenide and a preparation method and application thereof, and belongs to the field of organic synthesis. The 1,2,3-benzotriazine-4(3H)-ketone selenide has anti-schistosome activity. The preparation method has the advantages of mild conditions, easy control, high reaction efficiency, economical steps, cheap and easily available raw materials, no use of oxidants, good functional group tolerance and the like, and the prepared 1,2,3-benzotriazine-4(3H)-ketone selenide has high purity, the purity is 98.5-99.9%, and has great market promotion value. Compared with a multi-step synthesis reaction, the target product can be obtained through one-step reaction, the reaction yield reaches 90%, and the reaction has the advantages of high reaction efficiency and economical steps.

The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The application is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.

TIFF2025538048000094.tif34115 The present invention relates to novel compounds of formula (I), wherein P, Q, A, B, m, n, R 1 , R 2 and R 3 are defined as in Formula (I); which are negative allosteric modulators of metabotropic glutamate receptor subtype 7 (mGlu7) and are useful for treating or preventing neurological, otic, and psychiatric disorders associated with glutamate dysfunction, and disorders involving the mGlu7 subtype of metabotropic receptor. The present invention is also directed to pharmaceutical compositions comprising such compounds, processes for preparing such compounds and such compositions, and the use of such compounds for the prevention or treatment of neurological, otic, and psychiatric disorders involving mGlu7.

The embodiment of the invention discloses a method for determining multiple sun-screening agents in serum, the method can be used for determining the sun-screening agents, and the method comprises the following steps: obtaining a to-be-detected sample according to to-be-detected serum; performing chromatography and mass spectrometry on the to-be-detected sample under a predetermined detection condition to obtain peak area data corresponding to the multiple sun-screening agents; acquiring the concentration of each sun-screening agent in the serum to be detected according to the linear equation and the peak area data of each sun-screening agent; the multiple sun-screening agents comprise at least one of cresol trozole trisiloxane and ethyl hexyl triazinone.

The embodiment of the invention discloses a synthetic method of pyrrolo [2, 1-f] [1, 2, 4] triazine-4 (3H)-ketone. The synthesis method comprises the following steps: taking 2, 5-dimethoxytetrahydrofuran and tert-butyloxycarboryl hydrazine as initial raw materials, and sequentially carrying out Clawson-Kass pyrrole synthesis reaction, formylation reaction, deprotection group reaction and cyclization reaction to prepare pyrrolo [2, 1-f] [1, 2, 4] triazine-4 (3H)-ketone. Reagents and solvents used in the method are cheap and easy to obtain, reaction conditions of key steps are mild, a reliable technical scheme is provided for industrial production, and the method is a synthesis method with large-scale preparation value and has good application value.

The present invention relates to PDE9 inhibitors and their use for treating benign prostatic hyperplasia and sickle cell disease. The inhibitory compound can be selected from: 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one, 6-[3-(pyridin-3-yloxy)azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one, 6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro- imidazo[1,5-a]pyrazin-8-one, (3S,4S)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one, and (3R,4R)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one.

The present disclosure provides pyrazolo[5,1-f][1,2,4]triazin-4-ones that are inhibitors of NOX4, and are therefore useful for the treatment of diseases treatable by inhibition of NOX4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

The present invention relates to a cosmetic or pharmaceutical composition comprising at least one cosmetically or pharmaceutically acceptable excipient and a photoprotective system consisting of: (a) 5,6,5′,6′-tetraphenyl-3,3′-(1,4-phenylene)-bis[1,2,4]triazine, (b) 2,4-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, (c) hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, and (d) a solar filter selected from the group comprised of ethylhexyl triazone, diethylhexyl butamido triazone and 2-ethylhexyl salicylate, wherein the photoprotective system represents between 4% and 20% by weight of the composition relative to the total weight of the composition.

The present invention relates to a novel compound having the formula: 6-[[(3R)-1-ethyl-3-piperidinyl] amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1, 2, 4-triazine-5-one or 6-[[(3R)-1-ethyl-3-piperidinyl] amino]-3-(2-hydroxy-3-bicyclo [4.2. 0] oct-1, 3, 5-trialkenyl)-4-methyl-1, 2, 4-triazine-5-one, and a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising the same. Comprising the compound; and methods of using the compounds. # imgabs0 #

This invention relates to the fields of compound synthesis technology and pesticide technology, specifically to N-phenylthiotriazinone derivatives, their preparation methods, and applications. The N-phenylthiotriazinone derivatives are either N-phenylthiotriazinone derivatives containing oxime ester groups or N-phenylthiotriazinone derivatives containing oxime ether groups. The N-phenylthiotriazinone derivatives of this invention exhibit 100% control efficacy against six weeds at doses of 37.5-150 a.g. / ha. These compounds achieve good weed control effects at low doses and have relatively good safety profiles for crops such as corn, wheat, peanuts, soybeans, and cotton. They can be used as selective herbicides in agriculture. The compounds described in this invention can be developed and used as potential PPO inhibitors and post-emergence herbicides for broadleaf weeds. The derivatives have simple structures and preparation processes, low production costs, and broad application prospects.

The present invention provides a triazine ketone compound and its application. The structure of the compound is shown in Formula I: In Formula I, R1 and R2 are independently selected from any one of substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C6-C12 arylalkyl, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C3-C12 cycloalkylalkyl, substituted or unsubstituted C2-C12 heterocyclyl, substituted or unsubstituted C2-C12 heterocyclylalkyl, substituted or unsubstituted C4-C12 heteroaryl, and substituted or unsubstituted C4-C12 heteroarylalkyl. The triazine ketone compound provided by the present invention has high activity and can effectively inhibit the proliferation of prostate cancer cells.

The present invention relates to a topical preparation, the topical preparation comprising a combination of ultraviolet filters of a certain fine zinc oxide, 2,4-bis{[4-(2-ethylhexoxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine), 2-phenylbenzimidazole-5-sulfonic acid and / or one or more of its salts, and 4,4'-((6((4(((1,1-dimethylethyl)amino)carbonyl)phenyl)-amino)-1,3,5-triazin-2,4-diyl)diimino)bis(2-ethylhexyl) benzoate (INCI: diethylhexyl butamido triazone).

The present disclosure provides pyrazolo[5,1-f][1,2,4]triazin-4-ones that are inhibitors of NOX4, and are therefore useful for the treatment of diseases treatable by inhibition of NOX4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

The present invention relates to a sunscreen or daily care composition, the sunscreen or daily care composition comprising: (i) dicocoyl pentaerythritol distearyl citrate; and (ii) at least one organic UV filter, the present invention relates to a composition selected from the group consisting of disodium phenyl dibenzimidazole tetrasulfonate (DPDT), hexyl diethylaminohydroxybenzoylbenzoate (DHHB), butyl methoxydibenzoylmethane (BMDBM), p-xylylenedicamphorsulfonic acid (TDSA), ethylhexyl triazinone (EHT), diethylhexyl butyramido triazinone (DBT), phenylbenzimidazole sulfonic acid (PBSA), and one or more additives selected from the group consisting of: disodium phenyl dibenzimidazole tetrasulfonate (DPDT); the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition comprising: a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, and a silicone rubber composition comprising a silicone rubber composition, a silicone rubber composition comprising a silicone rubber composition, and a silicone rubber composition comprising a silicone rubber composition, furthermore, the present invention relates to the use of dicocoyl pentaerythritol distearyl citrate for improving the sun protection factor (SPF) and water resistance of a sunscreen or daily care composition comprising at least one organic UV filter and a corresponding method of use.